Following on from the Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) last month, the UK Post EBMT update meeting was held virtually last week where Dr Daniele Avenoso from Kings College Hospital, London presented data highlights from medac’s EBMT symposium, “Current Developments in Allogeneic Haematopoietic Stem Cell Transplantation: Recent Data on Treosulfan (Trecondi®).” The meeting was attended by over 100 delegates from UK hospitals and the presentation generated questions from attendees around preferred conditioning regimens and products.
Dr Daniele Avenoso presented data from Consultant Haematologists Professor Arnon Nagler (Israel) and Dr Friedrich Stölzel (Germany) which showed that a treosulfan reduced intensity conditioning regimen offers a new bone marrow transplant option for patients affected by neoplastic diseases. Further to this, the data showed that treosulfan based conditioning is not inferior to other conditioning regimens (all donor types) and may have better efficacy in patients with active disease.
The reduced toxicity of the new treosulfan/fludarabine-based regimen makes myeloablative conditioning an option for a broad range of adults and children that were not suitable for this treatment before now (AML and MDS, as well as for additional malignant and non-malignant diseases).
The clinical outcome shown in this presentation highlights that the treosulfan conditioning regimen in combination with fludarabine has the potential to become the new standard regimen for conditioning prior to allogeneic HSCT.